LYS PHARMA

Lys Pharma is a South Korean biotechnology company specializing in the development of pharmabiotics, which are therapeutic probiotics targeting the gut-brain axis. The company focuses on neurodegenerative diseases, particularly Parkinson's disease and Alzheimer's disease, by leveraging the microbiome to improve drug efficacy and patient outcomes. Their lead candidate, Lys-B01, is a specialized probiotic strain designed to enhance the metabolism of Levodopa and alleviate gastrointestinal symptoms in Parkinson's patients. Beyond its clinical pipeline, Lys Pharma commercializes a range of medical-grade supplements and health functional foods in South Korea. The company aims to provide holistic care for elderly patients through innovative microbial research and strategic clinical partnerships.